Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01388478 · ClinicalTrials.gov registry record · Phase 2

Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease

A Phase 2 study, sponsored by Virginia Commonwealth University.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT01388478: Completed Phase 2 study, sponsored by Virginia Commonwealth University.

NCT01388478 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01388478, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

By doing this study, researchers will examine the safety and tolerability of R-pramipexole in participants with Alzheimer's disease. This study will also examine the body and brain's response to the study drug by measuring the amount of injury to the cells (oxidative stress) in the blood and spinal fluid and brain imaging before and after treatment.

Primary Outcome

Labwork will be performed every two months. There will be frequent contact with subjects to assess for adverse events.

Interventions

  • DRUG R-pramipexole

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-07
Est. Completion 2014-04
Phase Phase 2
Virginia Commonwealth University

558 total trials

What the finished NCT01388478 record still lists

NCT01388478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 1 intervention - of which R-pramipexole is the first listed.

NCT01388478 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01388478 about?

NCT01388478 is a clinical study titled "Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease". By doing this study, researchers will examine the safety and tolerability of R-pramipexole in participants with Alzheimer's disease. This study will also examine the body and brain's response to the study drug by measuring the amount of injury to the cells (oxidative stress) in the blood and spinal ...

What is the current status of trial NCT01388478?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-07. Estimated completion is 2014-04.

What interventions are being tested in trial NCT01388478?

The interventions under investigation include: R-pramipexole (DRUG).

Who is sponsoring clinical trial NCT01388478?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01388478's enrollment target sits among peer trials

20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01388478, the US trial registry maintained by the National Library of Medicine. NCT01388478 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.